You are here: Home :: Area NEM :: Medical science :: Human medicine

Artur-Aron Weber, Thomas Hohlfeld, Sebastian Harder

Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic, antiinflammatory drugs? Arguments against

Keywords: arterial thrombosis, lipid mediators, inflammation, haemostasis, Clinical studies

The issue of the risk-benefit assessment of cyclooxygenase-2 (COX-2) inhibitors, as compared to traditional non-steroidal anti-inflammatory drugs (tNSAIDs), is far from being resolved. These compounds need to be carefully re-evaluated in order to avoid hasty conclusions, as it happened when COX-2 inhibitors were introduced into clinical practice. Several arguments support the concept, that COX-2 inhibitors remain a valuable therapeutic option at least for selected patients.

Thrombosis and Haemostasis, Schattauer

Print ISSN: 0340-6245
Volume: 96, 10/2006
Pages: 413 - 416

Show full article (external site)

Show all available items of this journal

 

Area NEM